ArticleJournal of cachexia, sarcopenia and muscle2015
Evidence for partial pharmaceutical reversal of the cancer anorexia-cachexia syndrome: the case of anamorelin.
Article in Journal of cachexia, sarcopenia and muscle, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Real-world effectiveness of anamorelin in patients with unresectable and relapse pancreatic cancer: a prospective observational study.Journal of gastrointestinal oncology · 2025Article
- Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model.Cancer science · 2022Article
- A case of squamous cell lung cancer treated with anamorelin in combination with a multidisciplinary collaborative approach for treating cancer cachexia.Respiratory medicine case reports · 2022Article
- The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers.Journal of cachexia, sarcopenia and muscle · 2021Article
- Sarcopenia: A Time for Action. An SCWD Position Paper.Journal of cachexia, sarcopenia and muscle · 2019Review
- Skeletal muscle wasting in chronic heart failure.ESC heart failure · 2018Review
- Treatment of sarcopenia: the road to the future.Journal of cachexia, sarcopenia and muscle · 2018Article
- Time to jump on the bandwagon: the Journal of Cachexia, Sarcopenia and Muscle in 2018.Journal of cachexia, sarcopenia and muscle · 2018Article
- Preventing muscle wasting by osteoporosis drug alendronate in vitro and in myopathy models via sirtuin-3 down-regulation.Journal of cachexia, sarcopenia and muscle · 2018Article
- Editorial: Geriatrics in the 21st Century.The journal of nutrition, health & aging · 2018Article
- Casting the net broader to confirm our imaginations: the long road to treating wasting disorders.Journal of cachexia, sarcopenia and muscle · 2017Article
- Acylated ghrelin treatment normalizes skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rat chronic heart failure.Journal of cachexia, sarcopenia and muscle · 2017Article
- Muscle wasting and sarcopenia in heart failure and beyond: update 2017.ESC heart failure · 2017Review
- Beta-hydroxy-beta-methylbutyrate supplementation and skeletal muscle in healthy and muscle-wasting conditions.Journal of cachexia, sarcopenia and muscle · 2017Review
- Anorexia of ageing: a key component in the pathogenesis of both sarcopenia and cachexia.Journal of cachexia, sarcopenia and muscle · 2017Article
- Welcome to the ICD-10 code for sarcopenia.Journal of cachexia, sarcopenia and muscle · 2016Article
- Frailty and sarcopenia in elderly.Wiener klinische Wochenschrift · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A major component of the cancer anorexia-cachexia syndrome is a decline in food intake. Up until now none of the drugs that improve appetite also improve skeletal muscle. Recent studies have suggested that the oral ghrelin-analog, anamorelin, increased food intake and muscle mass. Unfortunately, it does not increase muscle power. Its regulatory future is uncertain, although it has important clinical effects.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.